CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M

Reuters

2025/08/08

CytoSorbents <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M

CytoSorbents Corporation $(CTSO)$ has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY46935) on August 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557595180"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557595180\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557595180?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557595180","market":"fut","top_or_hot":-1,"title":"CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CytoSorbents <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CytoSorbents Corporation <a href=\"https://laohu8.com/S/CTSO\">$(CTSO)$</a> has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY46935) on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-08 04:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CytoSorbents <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CytoSorbents Corporation <a href=\"https://laohu8.com/S/CTSO\">$(CTSO)$</a> has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY46935) on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTSO","symbol_name":"Cytosorbents Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDLbjrQrV:1","article_id":"2557595180","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557595180","pubTimestamp":1754596836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CytoSorbents Corporation  has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"CTSO":"Cytosorbents Corporation"},"translate_title":"细胞吸附剂2025年第二季度业绩：收入增长9%至960万美元；运营亏损稳定在360万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTSO":0.9},"content_text":"CytoSorbents Q2 2025 Results: Revenue Up 9% to $9.6M; Operating Loss Steady at $3.6M\n    \n\n        CytoSorbents Corporation $(CTSO)$ has reported its financial results for the second quarter ending June 30, 2025. The company reported revenue of $9.6 million, marking an increase of 9% from $8.8 million in Q2 2024. This growth was mainly driven by a 22% year-over-year and sequential sales increase in Germany. The gross margin for the quarter was reported at 70.9%, compared to 73.5% in the same period last year. The operating loss remained flat at $3.6 million, consistent with Q2 2024. CytoSorbents has undertaken a reorganization of its German commercial team and sales approach, which initially caused a temporary sales disruption but has since shown promising results. The company anticipates that this reorganization will lead to enhanced execution and improved sales growth moving forward. CytoSorbents is focused on growing in key clinical applications, improving gross margins, and controlling costs to manage its core business towards near breakeven as it exits 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NY46935) on August 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}